Nasal-swab rapid tests failed to identify omicron infections for 2 to 3 days after saliva-based PCR tests identified high concentrations of viral RNA.

A new paper from @DrBlytheAdamson @robbysikka @awyllie13 and Prem Premsrirut has the details. 👇👏 1/4

medrxiv.org/content/10.110…
This means that rapid tests aren't catching people during their first few days of infection. But sensitive PCR tests are slowed by day++ turnarounds.

Suggests we're unlikely to test our way out of the current surge, even if we each had a week's supply of rapid tests at home. 2/4
One point which will not escape folks like @CaseyEMiddleton and @SBtotheDub is the "infectious" and "not infectious" annotations on the plot, based on N-gene RNA Ct.

While link between Ct and infectiousness is imperfect, the authors *also* directly document transmissions! ✅ 3/4
And...

More reinforcement of why preprint-sharing and #sciencetwitter are absolutely brilliant. Kudos to the authors for openly sharing their work quickly. Thank you! 4/4
After praising #sciencetwitter, let me tip the hat to @DiseaseEcology who noted that my comments combine issues associated w/ (1) saliva-vs-nasal specimen and (2) Ag tests.

Would saliva+Ag outperform nasal+Ag? Potentially, though unclear how much earlier. Would love data! [n+1]

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with Dan Larremore

Dan Larremore Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @DanLarremore

9 Dec 21
In populations with high vaccine coverage, wouldn't we actually *expect* many infections to be breakthroughs?

What would this mean for the impact of unvaccinated-only testing programs as vacc. rates increase?

These questions frame our new preprint. 1/

medrxiv.org/content/10.110…
By definition: when no one is vaccinated, 0% of infections are breakthroughs. When everyone is vaccinated, 100% of infections are breakthroughs.

So what happens in between?

Our study examines this question using a modeled population with mixed vax & prior infection status. 2/
Two things happen as vaccination rates increase:

1. Total infections decline—even imperfect vaccines reduce transmission.

2. The % of those infections that are breakthroughs increases, hitting 50/50 at 68% vax coverage in this scenario (35% prior inf. rate, VE≈2x mRNA). 3/
Read 19 tweets
12 Mar 21
Preprint: the relationship between SARS-CoV-2 viral load & transmission has been difficult to estimate.

Here, routine testing on a univ campus allows us to look at roommate pairs: viral loads were 6.5X higher when the index roommate transmitted. 1/

medrxiv.org/content/10.110…
This study starts with the observation that students who lived in multiple-occupancy rooms were more likely to test COVID-19+ by RT-PCR screening during the Fall 2020 semester.

This, in spite of higher testing rates among singles students. 2/
In multiple-occupancy rooms:
* only index roommate PCR+ in 398 rooms
* 2+ roommates PCR+ on same day in 44 rooms
* 2+ roommates PCR+ 1-14d apart in 116 rooms
* 2+ roommates PCR+ >14d apart in 6 rooms

This allows comparison between transmission & non-transmission rooms. 3/
Read 9 tweets
2 Feb 21
If you've already had COVID-19, would a *single* dose of Pfizer-BioNTech/Moderna provide a boost?

This brief report brings antibody titer data: yes.

This suggests a possible dose-sparing strategy to improve vaccine rollout... 1/4

medrxiv.org/content/10.110… Image
If vax & infection provided equivalent immunity, a dose-sparing strategy targeting seronegatives could be thought of as increasing vax supply (pic).

Ex: se 96.6%, sp 99.9% (Roche), 25% seroprev. = 32% increase in vax supply. 2/4

Modeled in this paper: science.sciencemag.org/content/early/… Image
But taking the idea from the medrxiv report cited above, and using *one* dose for each seropositive and *two* doses for each seronegative, one can derive a similar formula (pic).

Ex: se 96.6%, sp 99.9% (Roche), 25% seroprev. = 16% bonus vax supply. 3/4 Image
Read 6 tweets
21 Jan 21
Our recent work on vaccine prioritization for COVID-19 is now published in @ScienceMagazine, but this paper has evolved because of both formal and informal peer review. So while the paper is linked, here's a quick summary of the results. 🧵 1/

science.sciencemag.org/content/early/…
First, rather than reading another Twitter summary, there's a great discussion of this work in the broader context of vaccination strategies by two vaccine/modeling experts @MeaganCFitz @Alison_Galvani. Highly recommended for both theory & history. 2/

science.sciencemag.org/content/early/…
IMO there are 2 intuitive ideas in vaccine prioritization:
Intuition 1: directly protect the vulnerable.
Intuition 2: vaccinate to break transmission chains & indirectly protect vulnerable.

When intuition supports two opposing conclusions, don't use intuition—use math. 🤓 3/
Read 14 tweets
9 Dec 20
Updated preprint: Model-informed COVID-19 vaccine prioritization strategies by age and serostatus.

Smart suggestions from formal/informal review mean that the paper still asks how demographics, contacts, vax efficacy, & seroprevalence affect prioritization by age, but now...1/
We asked whether transmission-blocking properties affect prioritization. Intuitively, as the vaccine's transmission blocking properties become worse, direct protection of adults 60+ became/remained the clear best prioritization—across countries, R0 values, & vaccine supplies. 2/
Btw—there's a nice piece by @MollyEFG & team that shows why indirect effects are critical. In the medrxiv version of their NatMed editorial, they have this figure, showing how transmission blocking effects are *extremely* valuable at pop. scale. nature.com/articles/s4159… Image
Read 12 tweets
2 Dec 20
Preprint: COVID-19 screening and surveillance are critical, but molecular tests haven't come close to meeting needs, and temperature checks fail. We modeled the epidemiological impacts of using loss of smell as a screening symptom. Here's what we found. 1/ medrxiv.org/content/10.110…
Loss of smell is an interesting screening symptom because it's highly specific to COVID, precedes most other overt symptoms, and typically lasts ~1 week. Critically, its prevalence goes from ~45% when self-reported up to ~80% when a test is used. 2/
Contrast this with fever: ~20% prevalence, not specific to COVID, and lasts 1.5 days on average. So why do we still screen for fever? You can look for it in seconds with a contactless thermometer.

Could rapid, contactless, cheap tests for anosmia, impact transmission? 3/
Read 15 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal

Or Donate anonymously using crypto!

Ethereum

0xfe58350B80634f60Fa6Dc149a72b4DFbc17D341E copy

Bitcoin

3ATGMxNzCUFzxpMCHL5sWSt4DVtS8UqXpi copy

Thank you for your support!

Follow Us on Twitter!

:(